We evaluated an alternative pro-angiogenic strategy by blocking the inhibitory factor Nogo-A with antibodies18 and studied the effects of this treatment on the BBB in the peri-infarct region surrounding the stroke. This evidence concerns the gene RTN4 and stroke disorder.